RemeGen Co., Ltd. (OTCMKTS:REGMF) Short Interest Update

RemeGen Co., Ltd. (OTCMKTS:REGMF) was the target of a significant decline in short interest in the month of January. As of January 30th, there was short interest totaling 70,500 shares, a decline of 62.9% from the January 15th total of 190,000 shares. Based on an average trading volume of 0 shares, the days-to-cover ratio is currently ? days. Based on an average trading volume of 0 shares, the days-to-cover ratio is currently ? days.

RemeGen Price Performance

OTCMKTS REGMF opened at $10.45 on Thursday. RemeGen has a 1-year low of $9.81 and a 1-year high of $15.91. The stock’s 50 day moving average is $10.04 and its two-hundred day moving average is $8.90.

About RemeGen

RemeGen Co, Ltd. is a Shanghai-based biopharmaceutical company focused on the research, development and commercialization of innovative antibody-based therapeutics for oncology and immunology. Since its founding in 2009, RemeGen has built a portfolio of antibody–drug conjugates (ADCs), monoclonal antibodies and bispecific antibodies aimed at addressing a range of solid tumors and immune-related conditions. The company leverages its in-house discovery, engineering and manufacturing capabilities to advance its pipeline from preclinical stages through clinical trials.

RemeGen’s lead product candidate, Disitamab Vedotin (RC48), is a HER2-targeting ADC that has received regulatory approval in China for HER2-positive gastric cancer and urothelial carcinoma.